[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer [J]. Biomed Pharmacother, 2023, 169(23): 1-14.
[3] Dai ZT, Wu YL, Xu T, et al. The role of lncRNA SNHG14 in gastric cancer: enhancing tumor cell proliferation and migration, and mechanisms of CDH2 expression [J]. Cell Cycle, 2023, 22(23-24): 2522-2537.
[4] Xu L, Xu Y, Yang M, et al. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway [J]. BMC Pulm Med, 2020, 20(1): 266-276.
[5] Zhang L, Zhang Z, Zheng X, et al. A novel microRNA panel exhibited significant potential in evaluating the progression of laryngeal squamous cell carcinoma [J]. Noncoding RNA Res, 2023, 8(4): 550-561.
[6] Sun CC, Zhu W, Li SJ, et al. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway [J]. Genome Med, 2020, 12(1): 77-104.
[7] Chu PY, Wu HJ, Wang SM, et al. MAT2A localization and its independently prognostic relevance in breast cancer patients [J]. Int J Mol Sci, 2021, 22(10): 5382-5396.
[8] Chen YW, Du QR, He YJ, et al. Circ_0044516 regulates miR-136/MAT2A pathway to facilitate lung cancer development [J]. J Immunol Res, 2021, 15(1): 1-12.
[9] Zhao X, Wang L, Lin H, et al. Inhibition of MAT2A-related methionine metabolism enhances the efficacy of cisplatin on cisplatin-resistant cells in lung cancer [J]. Cell J, 2022, 24(4): 204-211.
[10] Chinese Medical Association, Oncology Branch. Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition) [J]. Chinese Journal of Oncology, 2024, 46(9): 805-843. (in Chinese)
中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版)[J]. 中华肿瘤杂志, 2024, 46(9): 805-843.
[11] Li Y, Wu X, Yang P, et al. Machine learning for lung cancer diagnosis, treatment, and prognosis [J]. Genom Proteom Bioinform, 2022, 20(5): 850-866.
[12] Zheng Y, Hu J, Li Y, et al. Clinicopathological and prognostic significance of circRNAs in lung cancer: a systematic review and meta-analysis [J]. Medicine (Baltimore), 2021, 100(14): 1-15.
[13] Wen T, Song L, Hua S. Perspectives and controversies regarding the use of natural products for the treatment of lung cancer [J]. Cancer Med, 2021, 10(7): 2396-2422.
[14] Dai J, Qu T, Yin D, et al. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer [J]. Cell Death Dis, 2023, 14(5): 312-326.
[15] Wang X, Yang P, Zhang D, et al. LncRNA SNHG14 promotes cell proliferation and invasion in colorectal cancer through modulating miR-519b-3p/DDX5 axis [J]. J Cancer, 2021, 12(16): 4958-4970.
[16] Chen X, Song P, Yao Y, et al. Long non-coding RNA SNHG14 regulates SPIN1 expression to accelerate tumor progression in non-small cell lung cancer by sponging miR-382-5p [J]. Cancer Manag Res, 2020, 12(1): 9113-9123.
[17] Hill M, Tran N. MiRNA interplay: mechanisms and consequences in cancer [J]. Dis Model Mech, 2021, 14(4): 1-11.
[18] Li H, Zhang LN, Song RJ, et al. MicroRNA-221 targets tissue inhibitor of metalloproteinases 2 to mediate the Akt/mTOR signaling pathway and affect xenograft tumor models of non-small cell lung cancer in mice [J]. Acta Anatomica Sinica, 2022, 53(6): 754-761. (in Chinese)
李辉, 张丽娜, 宋瑞佳, 等. 微小RNA-221靶向组织金属蛋白酶抑制因子2介导Akt/mTOR信号通路对非小细胞肺癌移植瘤小鼠模型的影响 [J]. 解剖学报, 2022, 53(6): 754-761.
[19] You J, Han Y, Qiao H, et al. Hsa_circ_0063804 enhances ovarian cancer cells proliferation and resistance to cisplatin by targeting miR-1276/CLU axis [J]. Aging (Albany NY), 2022, 14(11): 4699-4713.
[20] Zhang Z, Zhao H, Zhou G, et al. Circ_0002623 promotes bladder cancer progression by regulating the miR-1276/SMAD2 axis [J]. Cancer Sci, 2022, 113(4): 1250-1263.
[21] Xia S, Liang Y, Shen Y, et al. MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p [J]. J Bone Oncol, 2023, 41(1): 1-9.
[22] Luo H, Song Y, Zhang JA, et al. MAT2A facilitates PDCD6 methylation and promotes cell growth under glucose deprivation in cervical cancer [J]. Cell Death Discov, 2022, 8(1): 176-186.
[23] Cacciatore A, Shinde D, Musumeci C, et al. Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer [J]. Nat Commun, 2024, 15(1): 6672-6697.